Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 15;11:5878. doi: 10.1038/s41598-021-85412-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Tacrine and duloxetine promote remyelination after demyelination. Transmission electron microscopic images of transverse sections of the Tg(mbp:gal4-vp16;uas:gfp;uas:NTR-mCherry) larvae, with anterior to the left and dorsal to the top. (a–c) Representative images of ventral hemi-sections. M indicates Mauthner axon. Pseudo-colors were used to distinguish different degrees of myelination: blue indicates myelinated axons, pink indicates non-myelinated axons, and yellow indicates degenerated nerve structures. Scale bar, 2 μm. (d) Percentage of myelinated axons per ventral hemi-section. recovery: 53.4% ± 7.23, 250 nM tacrine: 69.2% ± 6.94, 10 μM duloxetine: 66.17% ± 8.23. (e) Quantification of the number of degenerated nerve structures per ventral hemi-section. Recovery: 9.86 ± 2.85; 250 nM tacrine: 5.83 ± 1.72; 10 μM duloxetine: 55.3 ± 2.07. (f) Quantification of the number of large caliber axons (> 1 μm) per ventral hemi-section. Recovery: 47.2 ± 5.36; 250 nM tacrine: 49.6 ± 2.30; 10 μM duloxetine: 47.8 ± 5.36. n = 5 for the recovery groups; n = 6 for the tacrine and duloxetine groups (g, h) Decreased g-ratio in myelinated axons in tacrine-treated larvae (blue line) and duloxetine-treated larvae (red line) compared to MTZ-treated larvae (black line); g-ratios: 0.86 ± 0.063; 250 nM tacrine: 0.81 ± 0.072, p < 0.001; 10 μM duloxetine: 0.4 ± 0.073, p < 0.05; n = 3. (i) Quantification of the number of myelinated axons per PLLn. Recovery: 12 ± 0.71, 250 nM tacrine: 12.2 ± 0.84, 10 μM duloxetine: 15.6 ± 0.55. (j–l) Representative sectioned images of PLL. Scale bar, 1 μm. ***p < 0.001; *p < 0.05; n.s., not significant.